Switching to Once-Weekly Insulin Icodec Versus Once-Daily Insulin Glargine U100 in Type 2 Diabetes Inadequately Controlled on Daily Basal Insulin: A Phase 2 Randomized Controlled Trial | Zendy

Harpreet S. Bajaj | Zendy; Richard M. Bergenstal | Zendy; Andreas Christoffersen | Zendy; Melanie J. Davies | Zendy; Amoolya Gowda | Zendy; Joakim Isendahl | Zendy; Ildiko Lingvay | Zendy; Peter Senior | Zendy; Robert Silver | Zendy; Roberto Trevisan | Zendy; Julio Rosenstock | Zendy

Open Access

Switching to Once-Weekly Insulin Icodec Versus Once-Daily Insulin Glargine U100 in Type 2 Diabetes Inadequately Controlled on Daily Basal Insulin: A Phase 2 Randomized Controlled Trial

Author(s) -

Harpreet S. Bajaj,

Richard M. Bergenstal,

Andreas Christoffersen,

Melanie J. Davies,

Amoolya Gowda,

Joakim Isendahl,

Ildiko Lingvay,

Peter Senior,

Robert Silver,

Roberto Trevisan,

Julio Rosenstock

Publication year - 2021

Publication title -

diabetes care

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 6.636

H-Index - 363

eISSN - 1935-5548

pISSN - 0149-5992

DOI - 10.2337/dc20-2877

Subject(s) - medicine , insulin glargine , insulin , diabetes mellitus , randomized controlled trial , basal insulin , endocrinology , basal (medicine) , type 2 diabetes , type 1 diabetes

Insulin icodec (icodec) is a novel once-weekly basal insulin analog. This trial investigated two approaches for switching to icodec versus once-daily insulin glargine 100 units/mL (IGlar U100) in people with type 2 diabetes receiving daily basal insulin and one or more oral glucose-lowering medications.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research